The Food and Drug Administration has placed a clinical hold on a CARDIO-TTR study of Ionis Pharmaceuticals Inc.'s (Nasdaq: IONS) IONIS-TTR in patients with TTR amyloid cardiomyopathy. The stock price plummeted $5.13 to close at $41.40.
Clinical hold placed on Ionis Pharmaceuticals study
April 07, 2016 at 17:01 PM EDT
